P
Patrizia Castellani
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 76
Citations - 4795
Patrizia Castellani is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Fibronectin & Angiogenesis. The author has an hindex of 34, co-authored 76 publications receiving 4532 citations. Previous affiliations of Patrizia Castellani include Schering AG & ETH Zurich.
Papers
More filters
Journal ArticleDOI
Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.
Laura Borsi,Enrica Balza,Marco Bestagno,Patrizia Castellani,Barbara Carnemolla,Attila Biro,Alessandra Leprini,Jorge Sepulveda,Oscar R. Burrone,Dario Neri,Luciano Zardi +10 more
TL;DR: The fact that ED‐B is 100% homologous in human and mouse, which ensures that L19 reacts equally well with the human and the murine antigen, should expedite the transfer of these reagents to clinical trials.
Journal ArticleDOI
The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis.
Patrizia Castellani,Giuseppe Viale,Alessandra Dorcaratto,Guido Nicolò,Janusz Kaczmarek,Germano Querzé,Luciano Zardi +6 more
TL;DR: It is demonstrated here, using immunohistochemical techniques, that while this FN isoform is undetectable in mature vessels, it is highly expressed during angiogenesis both in neoplastic and in normal tissues, as in the case of the functional layer of endometrium during the proliferative phase.
Journal ArticleDOI
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
Barbara Carnemolla,Laura Borsi,Enrica Balza,Patrizia Castellani,Raffaella Meazza,Alexander Berndt,Silvano Ferrini,Hartwig Kosmehl,Dario Neri,Luciano Zardi +9 more
TL;DR: This study shows that a fusion protein between L19 and interleukin 2 (L19-IL-2) mediates the selective delivery and concentration of IL-2 to tumor vasculature, thereby leading to a dramatic enhancement of the therapeutic properties of the cytokine.
Journal Article
Immunoscintigraphic Detection of the ED-B Domain of Fibronectin, a Marker of Angiogenesis, in Patients with Cancer
Monica Santimaria,G. Moscatelli,Giuseppe Viale,Leonardo Giovannoni,Giovanni Neri,Francesca Viti,Alessandra Leprini,Laura Borsi,Patrizia Castellani,Luciano Zardi,Dario Neri,P. Riva +11 more
TL;DR: The ability of L19(scFv)(2) to target tumors in patients provides the foundations for new therapeutic applications, in which the L19 antibody is engineered to selectively deliver bioactive molecules to primary tumors as well as to metastases.
Journal ArticleDOI
Selective targeted delivery of TNFα to tumor blood vessels
Laura Borsi,Enrica Balza,Barbara Carnemolla,Francesca Sassi,Patrizia Castellani,Alexander Berndt,Hartwig Kosmehl,Attila Biro,Annalisa Siri,Paola Orecchia,Jessica Grassi,Dario Neri,Luciano Zardi +12 more
TL;DR: L19mTNFα allows concentrating therapeutically active doses of T NFα at the tumor level, thus opening new possibilities for the systemic use of TNFα in cancer therapy.